Hodgkin Lymphoma News

Hodgkin Lymphoma (HL): Microenvironmental Biology Behind a Therapeutic Success Story - Oncodaily

Hodgkin Lymphoma (HL): Microenvironmental Biology Behind a Therapeutic Success Story Oncodaily

Non-Hodgkin lymphoma survivor thankful for clinical trial - UT MD Anderson

Non-Hodgkin lymphoma survivor thankful for clinical trial UT MD Anderson

Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors - Nature

Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors Nature

New Roundup weed killer class action settlement covers non-Hodgkin's lymphoma claims for up to 21 years - Yahoo

New Roundup weed killer class action settlement covers non-Hodgkin's lymphoma claims for up to 21 years Yahoo

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era - CancerNetwork

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era CancerNetwork

FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma - OncLive

FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma OncLive

Nodular lymphocyte-predominant Hodgkin lymphoma: Leah's story - Roswell Park Comprehensive Cancer Center

Nodular lymphocyte-predominant Hodgkin lymphoma: Leah's story Roswell Park Comprehensive Cancer Center

B-Cell Non-Hodgkin Lymphoma Clinical Trial Pipeline Expands as 75+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com

B-Cell Non-Hodgkin Lymphoma Clinical Trial Pipeline Expands as 75+ Companies Driving Innovation in the Therapeutics | DelveInsight Barchart.com

Low-Dose Nivolumab Offers Novel Strategy for Hodgkin Lymphoma Treatment - Targeted Oncology

Low-Dose Nivolumab Offers Novel Strategy for Hodgkin Lymphoma Treatment Targeted Oncology

Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma - The ASCO Post

Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma The ASCO Post

Learn About How Survival Rates Are Improving With Hodgkin Disease - Verywell Health

Learn About How Survival Rates Are Improving With Hodgkin Disease Verywell Health

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch

New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy - UT MD Anderson

New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy UT MD Anderson

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma - Nature

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma Nature

Bristol-Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment - Yahoo Finance

Bristol-Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment Yahoo Finance

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma - The ASCO Post

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma The ASCO Post

Durable 3-Year Superiority of N-AVD in Advanced Hodgkin Lymphoma - Targeted Oncology

Durable 3-Year Superiority of N-AVD in Advanced Hodgkin Lymphoma Targeted Oncology

Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin - UT MD Anderson

Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin UT MD Anderson

Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial - Nature

Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial Nature

Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials - Nature

Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials Nature

Sintilimab combined with AVD for the treatment of composite Hodgkin lymphoma and follicular lymphoma: a case report and literature review - Frontiers

Sintilimab combined with AVD for the treatment of composite Hodgkin lymphoma and follicular lymphoma: a case report and literature review Frontiers

A Rare Case of Non-Hodgkin Lymphoma of the Tracheobronchial Tree - Cureus

A Rare Case of Non-Hodgkin Lymphoma of the Tracheobronchial Tree Cureus

Impact of early failure of induction on transplant outcomes in Hodgkin lymphoma | Bone Marrow Transplantation - Nature

Impact of early failure of induction on transplant outcomes in Hodgkin lymphoma | Bone Marrow Transplantation Nature

T-Cell Therapy EB103 Demonstrates Safety in B-Cell Non-Hodgkin Lymphoma - Targeted Oncology

T-Cell Therapy EB103 Demonstrates Safety in B-Cell Non-Hodgkin Lymphoma Targeted Oncology

Young mother’s Hodgkin lymphoma diagnosis felt ‘devastating’ - Fred Hutchinson Cancer Center

Young mother’s Hodgkin lymphoma diagnosis felt ‘devastating’ Fred Hutchinson Cancer Center

FDA Approves Nivolumab (Opdivo) Combination for Classical Hodgkin Lymphoma - Oncology News Central

FDA Approves Nivolumab (Opdivo) Combination for Classical Hodgkin Lymphoma Oncology News Central

New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients - Roswell Park Comprehensive Cancer Center

New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients Roswell Park Comprehensive Cancer Center

Antibody-Based Therapies for the Treatment of Hodgkin Lymphoma in Older Patients - ASCO Publications

Antibody-Based Therapies for the Treatment of Hodgkin Lymphoma in Older Patients ASCO Publications

Miami F Marcus Allen has non-Hodgkin lymphoma, out for season - ESPN

Miami F Marcus Allen has non-Hodgkin lymphoma, out for season ESPN

Classic Hodgkin’s Lymphoma With Epstein–Barr Viremia and Lymphadenopathy - Wiley Online Library

Classic Hodgkin’s Lymphoma With Epstein–Barr Viremia and Lymphadenopathy Wiley Online Library

First-Line Options in Advanced-Stage Classical Hodgkin Lymphoma: Weighing Efficacy, Toxicity, and Quality of Life in Decision-Making - ASCO Daily News

First-Line Options in Advanced-Stage Classical Hodgkin Lymphoma: Weighing Efficacy, Toxicity, and Quality of Life in Decision-Making ASCO Daily News

Breast Mass as an Atypical Presentation of Non-Hodgkin Lymphoma - Cureus

Breast Mass as an Atypical Presentation of Non-Hodgkin Lymphoma Cureus

An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma - NEJM Evidence

An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma NEJM Evidence

Brentuximab Vedotin Combo Exhibits Efficacy in Early-Stage Hodgkin Lymphoma - CancerNetwork

Brentuximab Vedotin Combo Exhibits Efficacy in Early-Stage Hodgkin Lymphoma CancerNetwork

US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma - Reuters

US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma Reuters

Woman, 26, who diagnosed herself with cancer has stern message for the doctors that missed key symptom - UNILAD

Woman, 26, who diagnosed herself with cancer has stern message for the doctors that missed key symptom UNILAD

Transformation of Classical Hodgkin Lymphoma Into Non-Hodgkin Lymphoma: Three Case Reports From the West Bank - Wiley Online Library

Transformation of Classical Hodgkin Lymphoma Into Non-Hodgkin Lymphoma: Three Case Reports From the West Bank Wiley Online Library